Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.44 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.44 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.44 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.44 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4F8 | P98187 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16806011 | 0.87 | PDE4B (0.45) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL16806016 | 0.86 | CYP1A1 (0.54) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL16806029 | 0.82 | AKR1C3 (0.51) | HSD17B10SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL16805982 | 0.81 | KIT (0.45) | CYP1A2CYP3A4CYP2D6CYP2C19CD274 | |
| SCHEMBL16809183 | 0.80 | HCRTR1 (0.44) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL16806006 | 0.80 | ACHE (0.41) | CYP3A4CD274NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15906120 | 0.78 | ACHE (0.52) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL13241156 | 0.77 | ALDH1A1 (0.47) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL16805983 | 0.76 | MAPT (0.41) | CYP1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3120503 | 0.75 | TSHR (0.44) | CYP1A2CYP2C9CYP2C19HSD17B10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040966-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-06-22 | — | — | US | disclosed |
| WO-2020007964-A1 | 2-(2-AZABICYCLO[3.1.0]HEXAN-1-YL)-1H-BENZIMIDAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-01-09 | — | — | WO | disclosed |
| US-20190263797-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-08-29 | — | — | US | disclosed |
| US-10329287-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-25 | — | — | US | disclosed |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-26 | — | — | US | disclosed |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-26 | — | — | US | disclosed |
| US-9732075-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-15 | — | — | US | disclosed |
| US-9732075-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-15 | — | — | US | disclosed |
| EP-2855453-B1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-07 | — | — | EP | disclosed |
| US-20150166527-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-06-18 | — | — | US | disclosed |
| US-20150166527-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166527-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | CYP1A1 398/4885CYP1A2 834/4885CYP2E1 1046/4885 |
| US-10329287-B2 | Benzimidazole-proline derivatives | HCRTR1, HCRTR2, NPY1R | CYP1A1 445/4885CYP1A2 754/4885CYP2E1 1138/4885 |
| US-11040966-B2 | Benzimidazole-proline derivatives | HCRTR1, HCRTR2, NPY1R | CYP1A1 445/4885CYP1A2 754/4885CYP2E1 1138/4885 |
| US-20190263797-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | CYP1A1 445/4885CYP1A2 754/4885CYP2E1 1138/4885 |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | CYP1A1 445/4885CYP1A2 754/4885CYP2E1 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.